Clinical Trial Update: Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing cisplatin-pemetrexed versus carboplatin-paclitaxel-bevacizumab in KRAS-mutated non-small cell lung cancer is ongoing/unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• carboplatin-paclitaxel-bevacizumab
• cisplatin-pemetrexed

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Carcinoma, Non-Small Cell Lung | Phase 3 | Status: UNKNOWN